Publications by authors named "John Tavis"

Claim this Profile
C
Correction for Woodson et al., "Efficacy and pharmacological assessment of novel -hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors".
Molly E Woodson, Holly F Walden, M Abdul Mottaleb, Maria Makri, Georgia-Myrto Prifti, John E Tavis

Antimicrob Agents Chemother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and Biological Evaluation of Highly Potent Boronic Acid (Boronate Ester)-Bearing Heteroaryldihydropyrimidine Derivatives as HBV Capsid Assembly Modulators.
Yu Jin, Yang Sun, Shujie Zhao, Shuo Wang, Yutong Dou, John E Tavis

J Med Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines.
Chari Cohen, Thomas Tu, Philippa C Matthews, Su Wang, Jessica Hicks, John E Tavis

Lancet Gastroenterol Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scientific and medical evidence informing expansion of hepatitis B treatment guidelines.
Patrick T Kennedy, Lena Allweiss, Antonio Bertoletti, Markus Cornberg, Adam J Gehring, John E Tavis

Lancet Gastroenterol Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of -Hydroxypyridinedione-Based Inhibitors of HBV RNase H: Design, Synthesis, and Extended SAR Studies.
Dea Chotzalli, Vasiliki Pardali, Holly M Walden, Dimitrios Perivolaris, Dimitrios Moianos, John E Tavis

Int J Mol Sci· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting HBV with RNA interference: Paths to cure.
Matteo Iannacone, Cristian G Beccaria, Lena Allweiss, Julie Lucifora, John E Tavis

Sci Transl Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors.
Daniel P Bradley, Caleb J Valkner, Qilan Li, Makafui Gasonoo, Marvin J Meyers, John E Tavis

PLoS Pathog· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and pharmacological assessment of novel -hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors.
Molly E Woodson, Holly F Walden, M Abdul Mottaleb, Maria Makri, Georgia-Myrto Prifti, John E Tavis

Antimicrob Agents Chemother· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Availability of point-of-care HBV tests in resource-limited settings.
Daryl T Y Lau, Kathy Jackson, Camila A Picchio, Anna Kramvis, Mark Sonderup, John E Tavis

Lancet Gastroenterol Hepatol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Major open questions in the hepatitis B and D field - Proceedings of the inaugural International emerging hepatitis B and hepatitis D researchers workshop.
Thomas Tu, Jochen Wettengel, Yuchen Xia, Barbara Testoni, Margaret Littlejohn, John E Tavis

Virology· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro Enzymatic and Cell Culture-Based Assays for Measuring Activity of HBV Ribonuclease H Inhibitors.
Qilan Li, John E Tavis

Methods Mol Biol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-Hydroxypiridinedione: A Privileged Heterocycle for Targeting the HBV RNase H.
Dimitrios Moianos, Maria Makri, Georgia-Myrto Prifti, Aristeidis Chiotellis, Alexandros Pappas, John E Tavis

Molecules· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and assessment of the 1,6-dihydroxy-pyridin-2-one moiety as privileged scaffold for HBV ribonuclease H inhibition.
Erofili Giannakopoulou, Vasiliki Pardali, Tiffany C Edwards, Molly Woodson, Razia Tajwar, John E Tavis

Antiviral Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro evaluation of tropolone absorption, metabolism, and clearance.
Molly E Woodson, M Abdul Mottaleb, Ryan P Murelli, John E Tavis

Antiviral Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel 1,2,3-triazole isatin derivatives as potent SARS-CoV-2 3CLpro inhibitors click-chemistry-based rapid screening.
Xiangyi Jiang, Jing Li, Antonio Viayna, F Javier Luque, Molly Woodson, John Tavis

RSC Med Chem· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral Evaluation of Dispirotripiperazines against Hepatitis B Virus.
Thane Jones, John E Tavis, Qilan Li, Olga Riabova, Natalia Monakhova

J Med Chem· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological evaluation of novel sulfamoylbenzamide derivatives as HBV capsid assembly modulators.
Shuo Wang, Yujie Ren, Qilan Li, Ya Wang, Xiangyi Jiang, John E Tavis

Bioorg Chem· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Shenghua Gao, Letian Song, Tobias Claff, Molly Woodson, Katharina Sylvester, John Tavis

J Med Chem· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.
Shenghua Gao, Katharina Sylvester, Letian Song, Tobias Claff, Lanlan Jing, John Tavis

J Med Chem· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicted structure of the hepatitis B virus polymerase reveals an ancient conserved protein fold.
Razia Tajwar, Daniel P Bradley, Nathan L Ponzar, John E Tavis

Protein Sci· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metal coordinating inhibitors of Rift Valley fever virus replication.
Elizabeth Geerling, Valerie Murphy, Maria C Mai, E Taylor Stone, Andreu Gazquez Casals, John E Tavis

PLoS One· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection.
Tobias Boettler, Upkar S Gill, Lena Allweiss, Teresa Pollicino, John E Tavis

JHEP Rep· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-hydroxytropolones are noncompetitive inhibitors of human RNase H1 that bind to the active site and modulate substrate binding.
Nathan L Ponzar, Razia Tajwar, Nicola Pozzi, John E Tavis

J Biol Chem· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of Polyoxygenated Tropolones and their Antiviral Activity against Hepatitis B Virus and Herpes Simplex Virus-1.
Daniel V Schiavone, Diana M Kapkayeva, Qilan Li, Molly E Woodson, Andreu Gazquez Casals, John E Tavis

Chemistry· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The hepatitis B virus polymerase.
Daniel N Clark, Razia Tajwar, Jianming Hu, John E Tavis

Enzymes· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis